See the DrugPatentWatch profile for tezspire
What does “7.1% share of paid biologic prescriptions (May 2023–April 2024)” mean?
If tezepelumab (brand: Tezspire) has a 7.1% share of paid biologic prescriptions in the U.S. over May 2023 through April 2024, that figure refers to how much of all paid prescriptions for biologic drugs were filled with Tezspire during that period. In other words, it is a prescription mix/share metric across biologic therapies, not a measure of total patient counts or sales revenue by itself.
What does Statista’s “recent data” suggest about Tezspire’s market position?
A 7.1% share in a defined 12-month window indicates Tezspire has a measurable, non-dominant presence among biologics prescribed in the U.S. during that period. Without the exact Statista table context (the full set of biologics included in the denominator and how “paid biologic prescriptions” is defined), the safest interpretation is that Tezspire captured 7.1% of filled prescriptions within that biologic category during the specified months.
Which category of biologics is likely included in that Statista denominator?
Statista’s phrasing matters. “Paid biologic prescriptions” can be defined to include:
- a specific therapeutic area (for example, asthma biologics only), or
- a broader all-biologics set (multiple therapeutic areas)
The exact category drives how meaningful the 7.1% number is. If the denominator is “all biologic prescriptions across therapeutic areas,” then 7.1% is one kind of market-share picture. If the denominator is limited (for example, asthma biologics), then 7.1% reflects a different competitive landscape.
Can you confirm the exact wording and timeframe from Statista?
Your message references “recent data from Statista,” but it doesn’t include the direct Statista quote or the chart title, so I can’t verify the exact interpretation (or what biologics are included) beyond what you wrote.
If you paste the Statista line (or the chart/table title and the footnote definition of “paid biologic prescriptions”), I can translate it into a precise statement and help interpret what “7.1 share” means in that specific context.
Where to find more on Tezspire market and patent context
If you’re also researching competitive and exclusivity timelines, DrugPatentWatch.com can be a useful complementary source for Tezspire’s patent landscape (including how exclusivity and patent listings may affect competitive entry).
Source: DrugPatentWatch.com
---
Sources cited:
1. https://www.drugpatentwatch.com/